Sep 2, 2026 08:30AM
Aug 21, 2026 08:30AM
Aug 21, 2026 08:30AM
Aug 12, 2026 05:13PM
Aug 12, 2026 04:05PM
Aug 6, 2026 08:31AM
Aug 6, 2026 08:30AM RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
Aug 4, 2026 08:30AM
Jul 29, 2026 08:30AM
May 14, 2026 05:21PM
May 14, 2026 04:05PM
Apr 29, 2026 08:30AM
Mar 30, 2026 04:05PM
Mar 20, 2026 08:30AM RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
Dec 1, 2025 08:30AM
Nov 19, 2025 08:30AM
Nov 13, 2025 05:52PM
Nov 13, 2025 04:05PM
Oct 27, 2025 08:30AM
Aug 14, 2025 05:03PM
Aug 14, 2025 04:05PM RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on
Jul 14, 2025 08:30AM
May 15, 2025 05:54PM
May 15, 2025 04:05PM
May 1, 2025 08:30AM
Apr 1, 2025 08:30AM
Apr 1, 2025 08:30AM
Nov 14, 2024 08:00AM RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Dec 21, 2023 08:30AM
Dec 19, 2023 08:30AM
Dec 13, 2023 08:31AM
Dec 13, 2023 08:31AM
Nov 16, 2023 08:35AM
Nov 16, 2023 08:35AM
Nov 14, 2023 08:30AM RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
Aug 17, 2023 08:30AM
Jun 29, 2023 08:03AM
Jun 29, 2023 08:00AM
Jun 1, 2023 08:30AM
May 25, 2023 08:30AM
May 15, 2023 08:30AM
Apr 14, 2023 08:30AM RenovoRx (RNXT) Presenting Phase III Clinical Trial Interim Analysis Data
Apr 14, 2023 08:30AM
Apr 11, 2023 08:30AM
Mar 30, 2023 08:30AM
Mar 30, 2023 08:30AM
Mar 8, 2023 08:32AM
Mar 8, 2023 08:30AM
Mar 2, 2023 08:30AM RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Nov 14, 2022 08:30AM

1,223,225 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All